ImmunityBio
IBRX· Manufacturing· Fiscal year ends in December
Richard Adcock is the CEO of ImmunityBio and was paid $12.7M in FY2025 (Dec), up 16%.
Executives4
See all- 1Richard AdcockPresident and CEOFY2025
- 2Patrick Soon-Shiong, M.D.Global Chief Scientific and Medical OfficerFY2025
- 3David SachsCFOFY2025
- 4Regan LauerChief Accounting OfficerFY2025
Named executives and their total pay, from the Summary Compensation Table of the latest proxy.
Pay
See allImmunityBio paid its 4 named executives $30.0M in total in FY2025 (Dec). CEO Richard Adcock was paid $12.7M of that.
| Name | |||
|---|---|---|---|
| Richard AdcockPresident and CEO | |||
| Patrick Soon-Shiong, M.D.Global Chief Scientific and Medical Officer | |||
| David SachsCFO | |||
| Regan LauerChief Accounting Officer | Not disclosed | Not disclosed |
of each named executive, from the Summary Compensation Table of each proxy.
Peers12
See allThe FY2025 (Dec) proxy of ImmunityBio names 12 peer companies for pay. Among ImmunityBio and these peers, CEO pay was 3rd highest of 7 and total shareholder return was 6th highest of 7.
3rd highest of 7in ImmunityBio and its pay peers, FY2025 (Dec) by CEO pay:
6th highest of 7in ImmunityBio and its pay peers, FY2025 (Dec) by total shareholder return:
The comes from the company's proxy. CEO pay and of each company come from its own Pay versus Performance table for the same fiscal year.
Board2
See all- Cheryl L. CohenLead independent director · 6 yr on the boardIndependentAudit, Compensation—Paid as an executive
- Barry J. SimonDirector · 18 yr on the boardNot independent—Paid as an executive
The board of the latest proxy (FY2025).
Activity
Filings6
See all| Proxy statement | DEF 14A | Apr 30, 2026 | FY2025 |
| Annual report | 10-K | Feb 23, 2026 | FY2025 |
| Proxy statement | DEF 14A | Apr 30, 2025 | FY2024 |
| Annual report | 10-K | Mar 3, 2025 | FY2024 |
| Proxy statement | DEF 14A | Apr 29, 2024 | FY2023 |
| Annual report | 10-K | Mar 19, 2024 | FY2023 |
